Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Insulet (PODD), a developer of the Omnipod Insulin Management System, is highlighted as a compelling growth stock, boasting an 'A' Growth Style Score and 'A' VGM Score despite its Zacks #3 (Hold) rank. The company projects 42.9% year-over-year earnings growth for the current fiscal year, underpinned by eight upward analyst revisions for fiscal 2025, which increased the Zacks Consensus Estimate to $4.63 per share, and a strong average earnings surprise of +19.5%.

Analysis

Insulet Corporation (PODD) is presented as a strong candidate for growth-oriented investors, underscored by its top-tier 'A' ratings for both its Growth Style Score and overall VGM Score from Zacks. The company's fundamental growth outlook is robust, with a forecasted year-over-year earnings growth of 42.9% for the current fiscal year. This positive forward view is further substantiated by recent analyst activity, where eight analysts have revised their fiscal 2025 earnings estimates upwards over the last 60 days. This collective sentiment shift has lifted the Zacks Consensus Estimate for FY2025 by $0.28 to $4.63 per share. The company's operational execution is also notable, demonstrated by a consistent history of outperformance with an average positive earnings surprise of 19.5%. A key point of consideration is the dissonance between these strong growth indicators and the stock's neutral Zacks #3 (Hold) rank, which suggests that while long-term growth prospects are compelling, near-term catalysts may be less certain or that valuation is a moderating factor.

Key Decisions for Investors

• Growth-focused investors should consider PODD for their watchlists, given the powerful combination of a 42.9% projected EPS growth rate and a top-tier 'A' Growth Score.
• It is prudent to investigate the factors behind the neutral Zacks #3 (Hold) rank, as this could signal valuation concerns or a lack of immediate catalysts not fully reflected in the strong long-term growth metrics.
• Monitor future analyst estimate revisions closely, as the trend of upward revisions for fiscal 2025 is a critical pillar supporting the current bullish growth thesis for the stock.